Showing results (231-240 of 533) with videos related to
Sort By:
Pageof 54
Prostaglandins|August 1, 1978
Inflammatory effects of prostacyclin (PGI2) and 6-oxo-PGF1alpha in the rat pawE A Higgs, S Moncada, J R VaneEuropean Journal of Pharmacology|September 23, 1987
Comparative pharmacology of EDRF and nitric oxide on vascular stripsP J Hutchinson, R M Palmer, S MoncadaThe Journal of Pharmacology and Experimental Therapeutics|October 1, 1980
Prostacyclin and thromboxane A2 synthesis by rabbit pulmonary arteryP M Salzman, J A Salmon, S MoncadaBritish Journal of Pharmacology|October 1, 1990
Characterization of the L-arginine:nitric oxide pathway in human plateletsM W Radomski, R M Palmer, S MoncadaProstaglandins|March 1, 1985
Evaluation of inhibitors of eicosanoid synthesis in leukocytes: possible pitfall of using the calcium ionophore A23187 to stimulate 5' lipoxygenaseJ A Salmon, L C Tilling, S MoncadaEuropean Journal of Pharmacology|May 20, 1988
Effect of SKF 525A on the release of nitric oxide and prostacyclin from endothelial cellsD D Rees, R M Palmer, S MoncadaEuropean Journal of Clinical Investigation|December 1, 1990
Arterial wall hypoxia following hyperfusion through the vasa vasorum is an initial lesion in atherosclerosisJ F Martin, R F Booth, S MoncadaBritish Journal of Pharmacology|October 1, 1994
Effect of nitric oxide gas on the generation of nitric oxide by isolated blood vessels: implications for inhalation therapyR J Kiff, D W Moss, S MoncadaLancet (London, England)|January 1, 1977
Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregationS Moncada, E A Higgs, J R VaneProstaglandins|March 1, 1977
Effects of prostacyclin (PGX) on cyclic AMP concentrations in human plateletsJ E Tateson, S Moncada, J R VanePageof 54